Literature DB >> 31642940

Homotrimeric MMP-9 is an active hitchhiker on alpha-2-macroglobulin partially escaping protease inhibition and internalization through LRP-1.

Xena Serifova1, Estefania Ugarte-Berzal1, Ghislain Opdenakker1, Jennifer Vandooren2.   

Abstract

Proteolysis is a crucial process in life, tightly controlled by numerous natural protease inhibitors. In human blood, alpha-2-macroglobulin is an emergency protease inhibitor preventing coagulation and damage to endothelia and leukocytes. With the use of a unique protease trapping mechanism, alpha-2-macroglobulin lures active proteases into its snap-trap, shields these from potential substrates and 'flags' their complex for elimination by receptor-mediated endocytosis. Matrix metalloprotease-9/gelatinase B is a secreted protease increased in blood of patients with inflammations, vascular disorders and cancers. Matrix metalloprotease-9 occurs as monomers and stable homotrimers, but the reason for their co-existence remains obscure. We discovered that matrix metalloprotease-9 homotrimers undergo reduced anti-proteolytic regulation by alpha-2-macroglobulin and are able to travel as a proteolytically active hitchhiker on alpha-2-macroglobulin. As a comparison, we revealed that monomeric active matrix metalloprotease-9 is efficiently trapped by human plasma alpha-2-macroglobulin and this masks the detection of activated matrix metalloprotease-9 with standard analysis techniques. In addition, we show that alpha-2-macroglobulin/trimer complexes escape clearance through the receptor low-density lipoprotein receptor-related protein 1, also known as the alpha-2-macroglobulin receptor. Thus, the biochemistry and biology of matrix metalloprotease-9 monomers and trimers are completely different as multimerization enables active matrix metalloprotease-9 to partially avoid alpha-2-macroglobulin regulation both by direct protease inhibition and by removal from the extracellular space by receptor-mediated endocytosis. Finally, for the biomarker field, the analysis of alpha-2-macroglobulin/protease complexes with upgraded technology is advocated as a quotum for protease activation in human plasma samples.

Entities:  

Keywords:  Endocytosis; LRP-1; MMP-9; Proteolysis; α2M

Year:  2019        PMID: 31642940     DOI: 10.1007/s00018-019-03338-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  9 in total

1.  Sialic acid removal by trans-sialidase modulates MMP-2 activity during Trypanosoma cruzi infection.

Authors:  Daniel Musikant; Romina Higa; Cristina E Rodríguez; Martin M Edreira; Oscar Campetella; Alicia Jawerbaum; María S Leguizamón
Journal:  Biochimie       Date:  2021-04-20       Impact factor: 4.079

Review 2.  Natural Marine and Terrestrial Compounds as Modulators of Matrix Metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimer's Disease.

Authors:  Lidia Ciccone; Jennifer Vandooren; Susanna Nencetti; Elisabetta Orlandini
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-24

Review 3.  Challenges in Matrix Metalloproteinases Inhibition.

Authors:  Helena Laronha; Inês Carpinteiro; Jaime Portugal; Ana Azul; Mário Polido; Krasimira T Petrova; Madalena Salema-Oom; Jorge Caldeira
Journal:  Biomolecules       Date:  2020-05-05

4.  Bivalent Inhibitor with Selectivity for Trimeric MMP-9 Amplifies Neutrophil Chemotaxis and Enables Functional Studies on MMP-9 Proteoforms.

Authors:  Elisa Nuti; Armando Rossello; Doretta Cuffaro; Caterina Camodeca; Jens Van Bael; Dries van der Maat; Erik Martens; Pierre Fiten; Rafaela Vaz Sousa Pereira; Estefania Ugarte-Berzal; Mieke Gouwy; Ghislain Opdenakker; Jennifer Vandooren
Journal:  Cells       Date:  2020-07-07       Impact factor: 6.600

Review 5.  Alpha-2-Macroglobulin in Inflammation, Immunity and Infections.

Authors:  Jennifer Vandooren; Yoshifumi Itoh
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

Review 6.  How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?

Authors:  Ghislain Opdenakker; Séverine Vermeire; Ahmed Abu El-Asrar
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

7.  Structural characterisation of inhibitory and non-inhibitory MMP-9-TIMP-1 complexes and implications for regulatory mechanisms of MMP-9.

Authors:  Łukasz Charzewski; Krystiana A Krzyśko; Bogdan Lesyng
Journal:  Sci Rep       Date:  2021-06-28       Impact factor: 4.379

8.  An Oral Rinse Active Matrix Metalloproteinase-8 Point-of-Care Immunotest May Be Less Accurate in Patients with Crohn's Disease.

Authors:  Jaana Rautava; Ulvi K Gürsoy; Adrian Kullström; Eija Könönen; Timo Sorsa; Taina Tervahartiala; Mervi Gürsoy
Journal:  Biomolecules       Date:  2020-03-04

Review 9.  Infarct in the Heart: What's MMP-9 Got to Do with It?

Authors:  Mediha Becirovic-Agic; Upendra Chalise; Michael J Daseke; Shelby Konfrst; Jeffrey D Salomon; Paras K Mishra; Merry L Lindsey
Journal:  Biomolecules       Date:  2021-03-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.